A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Attention Deficit Hyperactivity Disorder (ADHD) affects around 3–5% of UK adults and children, with symptoms including inattention, hyperactivity, and impulsivity. Standard treatments (stimulants like methylphenidate, non-stimulants, behavioural therapy) work for many, but some patients experience limited benefits or side effects. In 2025, a small but growing number of private specialist clinics prescribe CBPMs for ADHD symptoms when conventional options have been insufficient.
This guide covers current evidence, access, product considerations, and risks.
1. Evidence for CBPMs in ADHD (2025 Update)
Evidence is preliminary and mostly observational — no large-scale RCTs exist for CBPMs in ADHD.
- Real-World UK Data UK Medical Cannabis Registry and private clinic outcomes show some patients with ADHD report improvements in focus, impulsivity, hyperactivity, and emotional regulation at 1–6 months. A small subset use CBPMs as adjunctive therapy (alongside stimulants). Anecdotal reports are positive for some, but not universal.
- CBD-Focused Evidence CBD may help with hyperactivity, impulsivity, and sleep issues in some neurodevelopmental studies (small trials, mostly children). It has a calming effect without psychoactive risks.
- THC and Balanced Products Low-dose THC may aid focus and emotional regulation in some adults, but high doses can worsen inattention or anxiety. Balanced THC/CBD products are more commonly prescribed in private practice.
- NHS Position NICE and NHS England do not recommend CBPMs for ADHD. NHS access is extremely rare (not approved for this indication).
- Limitations Data is mostly from patient registries and case series. No robust placebo-controlled trials. Long-term effects, optimal dosing, and age-specific risks (especially children) are under-researched. Some patients report no benefit or worsening symptoms.
2. Access for ADHD in 2025
NHS — Virtually impossible for ADHD alone (not NICE-approved).
Private Clinics — Emerging but limited. Eligibility: Diagnosed ADHD, 2+ conventional treatments tried (e.g., stimulants, non-stimulants, therapy) with insufficient benefit/side effects, medical records.
Process (Private)
- Self-refer to CQC-regulated clinic (e.g., Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe).
- Online eligibility check/upload records.
- Specialist consultation (£50–£200).
- Prescription if suitable (often CBD-dominant or low-THC balanced).
- Medication from licensed pharmacy (home delivery).
- Follow-ups (1–3 months).
Costs
- Consultation: £50–£200
- Medication: £50–£300+/month (CBD-dominant often cheaper)
- Follow-ups: £65–£150
3. CBD vs THC for ADHD
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Effects on ADHD | May reduce hyperactivity, impulsivity, improve focus/sleep | Low dose may aid focus/emotional regulation; high dose can worsen inattention/anxiety |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, capsules |
| Evidence | Preliminary positive for some symptoms | Mixed; real-world reports vary |
| Risks | Lower (fatigue, appetite changes rare) | Higher (cognitive impairment, dependence, anxiety) |
| UK Private Use | Often first-line for ADHD | Used cautiously when CBD alone insufficient |
Clinics usually start with CBD-dominant/low-THC due to lower risk profile.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, appetite changes
- THC-related: Potential worsening of inattention, anxiety, dependence, cognitive effects (especially in young people)
- General: Interactions with stimulants/non-stimulants, psychiatric effects in vulnerable individuals
- Children/Young People: Very limited data — most clinics are cautious and rarely prescribe for under-18s
Specialists monitor closely and start low/slow.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for ADHD — full private cost.
Sources
- UK Medical Cannabis Registry patient outcomes
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Observational studies on cannabinoids and ADHD (2023–2025)
- Clinic data (Releaf, Alternaleaf, Curaleaf)